Intrinsiqs

Is BridgeBio Oncology Therapeutics Inc. overvalued?

BridgeBio Oncology Therapeutics Inc. (BBOT) — key valuation metrics and fundamentals.

No verdict
Price
$9.06
Fair value
Current P/E
Normal P/E
Market cap
$725.8M
Dividend yield
0.0%
Return on equity
-61.5%
Sector
Healthcare

See the full interactive analysis →

Fair value compares BBOT's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.